Flora Growth Corp. (FLGC) Announces Q3 Loss and Falls Short of Revenue Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Source: NASDAQ.COM
Quarterly Loss Report: Flora Growth Corp. reported a quarterly loss of $4.93 per share, significantly worse than the Zacks Consensus Estimate of a loss of $2.13, marking an earnings surprise of -131.46%. The company's revenues also fell short, totaling $9.75 million, which is a 22.14% miss compared to estimates.
Stock Performance: The company's shares have declined approximately 76.7% since the beginning of the year, contrasting with a 15.1% gain in the S&P 500, raising concerns about the stock's future performance.
Earnings Outlook: The current consensus EPS estimate for the upcoming quarter is -$1.97 on revenues of $11.56 million, while the fiscal year estimate is -$23.01 on $50.66 million in revenues. The mixed trend in earnings estimate revisions has resulted in a Zacks Rank #3 (Hold) for the stock.
Industry Context: Flora Growth operates within the Medical - Products industry, which is currently ranked in the bottom 40% of Zacks industries, indicating potential challenges ahead. Investors are advised to consider industry performance when evaluating the stock's outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLFS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLFS
Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 33.20 USD with a low forecast of 32.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.580
Low
32.00
Averages
33.20
High
34.00
Current: 22.580
Low
32.00
Averages
33.20
High
34.00
About BLFS
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioLife Solutions Reports Q4 Revenue of $24.8M, Up 20% Year-Over-Year
- Significant Revenue Growth: BioLife Solutions reported preliminary Q4 unaudited revenue from continuing operations of $24.8 million, reflecting a 20% year-over-year increase, which underscores the company's strong performance in the cell and gene therapy market and solidifies its market position.
- Full-Year Performance Exceeds Expectations: For FY2025, the company achieved $96.2 million in continuing operations revenue, surpassing the high end of previously raised guidance by 29%, indicating robust growth driven by its biopreservation product line and boosting investor confidence.
- Strategic Focus Transformation: Following the divestiture of the evo product line in 2025, BioLife is now positioned as a pure-play cell processing company focused on high-value, recurring revenue franchises, which is expected to drive future profitability and long-term value creation.
- Optimistic Future Outlook: The company anticipates revenue growth across its product portfolio in 2026, along with further expansion of adjusted EBITDA margins, indicating sustained competitiveness and profitability in the market.
Continue Reading
Pinnacle Financial Partners Trading 32.3% Below Fair Value Amid Growth Prospects
- Market Strength: As of the end of 2025, the U.S. stock market is notably strong, with the S&P 500 reaching all-time highs, reflecting investor confidence amid rising precious metal prices and stable Treasury yields.
- Pinnacle Financial Overview: Pinnacle Financial Partners has a market cap of $7.79 billion and generates $1.89 billion in annual revenue, with earnings and revenue expected to grow significantly over the next three years, despite a low forecasted return on equity of 11.3%.
- M&A Impact: The recent regulatory approval for Pinnacle's merger with Synovus Financial Corp is expected to positively influence future performance, with integration efforts projected to be completed by 2027, enhancing market competitiveness.
- Other Undervalued Stocks: In the U.S. market, companies like Zymeworks, UMB Financial, and Sportradar show significant undervaluation potential, with estimated discounts ranging from 48% to 49%, attracting investor interest.
Continue Reading